TRAX
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
NASDAQ: TRAXV · HEALTHCARE · BIOTECHNOLOGY
$22.51
+0.00% today
Updated 2026-04-30
Market cap
$782.20M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$—
Dividend yield
—
52W range
$15 – $27
Volume
0.0M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+4.0
Profitability
C5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-126.16M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net income | $-106.15M | $-163.71M | $-163.71M |
| EPS | — | — | $— |
| Free cash flow | $-93.81M | $-126.16M | $-126.16M |
| Profit margin | — | — | — |
Peer comparison
Smart narrative
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued trades at $22.51. Our Smart Value Score of 23/100 indicates the stock is weak.
Frequently asked questions
What is First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's stock price?
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) trades at $22.51.
Is First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell).
What is the price target of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV)?
The analyst target price is $—, representing NaN% downside from the current price of $22.51.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE—
Beta—
50D MA$21.41
200D MA$21.41
Shares out0.03B
Float—
Short ratio—
Avg volume0.0M
Performance
1 week+0.00%
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—